LTS' asenapine TTS

LTS is pleased to announce that the European Patent Office has issued their decision to grant an European Patent (EP 3338768 B1) for LTS’ application relating to an asenapine transdermal therapeutic system (TTS).

The asenapine TTS is a twice-weekly transdermal patch for the treatment of schizophrenia and is one of LTS’ proprietary projects. The LTS asenapine TTS has successfully completed a Phase I clinical study and further patent applications covering the development have been filed.

For more information on this partnering opportunity, please contact: